Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand BioSpaceAnalysts tentatively welcomed Novo's new corporate rebrand--so long as it comes with a larger change to the company's overall business strategy.Read full story pharminent September 14, 2026 (Last updated: September 16, 2026) BioSpace Analysts tentatively welcomed Novo’s new corporate rebrand–so long as it comes with a larger change to the company’s overall business strategy. Read full story Post navigation Previous: Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approvalNext: Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026